### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $\begin{array}{l} Introduced\ 01/07/96\ \ Origin: Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13 \end{array}$ 

Name	Name of entity		
Livel	lire Limited		
ABN 59 15	ABN 59 153 266 605		
	the entity) give ASX the following	information.	
	ust complete the relevant sections (attach	sheets if there is not enough space).	
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Fully paid ordinary shares issued on conversion of performance rights ( <b>Shares</b> ).	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	50,000 Shares.	
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares on the same terms as all other ordinary shares on issue.	

Yes. The Shares rank equally with all other Do the \*securities rank equally in all respects from the +issue ordinary Shares in the Company. date with an existing +class of quoted \*securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a distribution) trust. interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration Nil, the Shares have been issued upon conversion of unlisted performance rights. Purpose of the issue 6 The Shares have been issued to an employee (If issued as consideration for of 50,000 upon conversion unlisted the acquisition of assets, clearly performance rights which were issued under identify those assets) the Company's Employee Incentive Plan (EIP). Is the entity an \*eligible entity 6a that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 23 November 2017 resolution under rule 7.1A was passed 6с Number of \*securities issued Nil. without security holder approval under rule 7.1 Number of \*securities issued 6d Nil. with security holder approval

under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	50,000 Shares issued number of performanc	on conversion of that e rights.
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 17,260,830 7.1A: 24,205,632	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	8 February 2018	
		<b>-</b>	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 183,072,926	+Class Fully paid ordinary shares  * 8,450,039 shares are subject to voluntary escrow restrictions
		NY 1	101
0	Manufacture 1 +1 C 2	Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	78,031,021	Fully paid ordinary shares (escrowed to 10 June 2018)
		16,600,000	Unlisted Options (exercisable at \$0.25; expiring 1 June 2020;

	escrowed to 10 June 2018; subject to vesting conditions)
2,500,000	Unlisted Options (exercisable at \$0.188446; expiring 14 October 2020; subject to vesting conditions)
1,479,815	Performance Rights (subject to vesting conditions)
1,000,000	Unlisted Options (exercisable at \$0.3814; expiring 12 January 2021; subject to vesting conditions)
4,500,000	Unlisted Options (exercisable at \$0.6036 expiring 1 August 2021; subject to various vesting conditions)
1,000,000	Unlisted Options (exercisable at \$0.6927; expiring 10 August 2021; subject to various vesting conditions)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

#### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the <sup>+</sup> securities will be offered	N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A

27	and holde exerc	ise, the date on which es will be sent to option	N/A
28		rights trading will begin (if cable)	N/A
29		rights trading will end (if cable)	N/A
30		do security holders sell their ements in full through a er?	N/A
31		-	N/A
32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	<sup>+</sup> Issue	e date	N/A
	ed only c	Quotation of second of the complete this section if you are appointed of the control of the cont	
(a)		<sup>+</sup> Securities described in Part	1
(b)			nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

35		securities, the names of the 20 largest holders of the ne number and percentage of additional *securities
36		securities, a distribution schedule of the additional mber of holders in the categories
37	A copy of any trust deed for t	he additional <sup>+</sup> securities
Entit	ies that have ticked box 3	4(b)
38	Number of *securities for which *quotation is sought	50,000 Shares.
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	Fully paid ordinary shares.
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes, the Shares rank equally with all other ordinary Shares in the Company.
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)	Conversion of 50,000 performance rights into that number of Shares.
		Number +Class

42	Number and <sup>+</sup> class of all	183,072,926	fully paid ordinary
	+securities quoted on ASX		shares
	( <i>including</i> the <sup>+</sup> securities in clause 38)		
	30)		

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	 Date: 8 February 2018

(Company secretary)

Print name: Charly Duffy

== == == ==

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note: <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	500,000 shares issued upon the exercise of that number of unlisted options on 13 February 2017.  28,500,000 Shares issued 3 April 2017 approved at the meeting held on 23 November 2017.  225,446 shares issued on conversion of that number of performance rights on 20 September 2017.  1,927,657 Loan Back Shares issued on 20 September 2017 under the Employee Incentive Plan.  7,700,000 Loan Back Shares issued on 29 November 2017 approved at the meeting held on 23 November 2017.  161,148 shares issued on conversion of that number of performance rights on 17 January 2018.  50,000 shares issued on conversion of that number of performance rights on 8 February 2018.	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	N/A	
"A"	242,056,328	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	36,308,449	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period not counting those issued:	19,047,619 Shares issued on 14 December 2017.	
• Under an exception in rule 7.2		
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	19,047,619	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	36,308,449	
Note: number must be same as shown in Step 2		
Subtract "C"	19,047,619	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	17,260,830	
	[Note: this is the remaining placement capacity under rule 7.1]	

04/03/2013 Appendix 3B Page 11

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	24,205,632	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<ul> <li>Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</li> <li>Notes:         <ul> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>		
"E"	Nil	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	24,205,632
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	24,205,632
	Note: this is the remaining placement capacity under rule 7.1A

04/03/2013 Appendix 3B Page 13

<sup>+</sup> See chapter 19 for defined terms.